Zynex, Inc. (NASDAQ:ZYXI) Shares Acquired by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC boosted its stake in shares of Zynex, Inc. (NASDAQ:ZYXI) by 10.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 159,259 shares of the company’s stock after purchasing an additional 14,820 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Zynex were worth $1,276,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Sei Investments Co. increased its stake in shares of Zynex by 32.3% in the second quarter. Sei Investments Co. now owns 21,717 shares of the company’s stock valued at $202,000 after purchasing an additional 5,300 shares during the period. Millennium Management LLC lifted its holdings in Zynex by 66.5% in the second quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock worth $2,769,000 after purchasing an additional 118,615 shares during the period. Investment Partners Asset Management Inc. bought a new position in Zynex in the 3rd quarter valued at about $96,000. GSA Capital Partners LLP increased its stake in Zynex by 72.7% during the 3rd quarter. GSA Capital Partners LLP now owns 79,930 shares of the company’s stock valued at $652,000 after buying an additional 33,649 shares during the period. Finally, Royce & Associates LP raised its position in shares of Zynex by 9.2% during the 3rd quarter. Royce & Associates LP now owns 257,291 shares of the company’s stock worth $2,099,000 after buying an additional 21,781 shares in the last quarter. 29.68% of the stock is currently owned by institutional investors.

Zynex Price Performance

Shares of Zynex stock opened at $8.06 on Wednesday. Zynex, Inc. has a 1-year low of $7.15 and a 1-year high of $13.77. The firm has a fifty day simple moving average of $8.10 and a 200-day simple moving average of $8.18. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $256.68 million, a price-to-earnings ratio of 53.73 and a beta of 0.53.

Insider Activity at Zynex

In other news, CFO Daniel J. Moorhead sold 10,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $8.08, for a total value of $80,800.00. Following the completion of the transaction, the chief financial officer now directly owns 35,190 shares of the company’s stock, valued at approximately $284,335.20. This represents a 22.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold 36,000 shares of company stock worth $288,860 over the last three months. Company insiders own 52.13% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on ZYXI. Royal Bank of Canada cut their price target on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Zynex in a report on Friday, December 6th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.